AstraZeneca (NASDAQ:AZN) and Daiichi Sankyo said on Friday that the European Medicines Agency (EMA) endorsed ENHERTU for the ...

Approval would expand the use of Enhertu to breast cancer patients with nearly undetectable HER2 levels in their tumors.

(Alliance News) - AstraZeneca PLC on Friday said its breast cancer therapy, Enhertu, which is being developed jointly with Tokyo-based pharmaceutical company Daiichi Sankyo Co Ltd, has been ...

The European Union's health regulator on Friday backed AstraZeneca and Daiichi Sankyo's drug Enhertu as a breast cancer ...

Daiichi Sankyo and AstraZeneca’s Enhertu has been recommended for approval in the European Union as a monotherapy for the treatment of adult patients with unresectable or metast ...

AstraZeneca (AZN) and Daiichi Sankyo’s (DSNKY) trastuzumab deruxtecan has been recommended for approval in the European Union as a monotherapy ...

The Orphan Drugs Market is experiencing significant growth due to increasing investment in rare disease research, regulatory incentives, and advancements in biotechnology. Orphan drugs are specialized ...

Researchers conduct a retrospective, population-based cohort study of adult patients with metastatic breast cancer who underwent genomic profiling at academic institutions.

The breast cancer market has experienced robust growth, fueled by increased awareness and early detection efforts. Advances in diagnostic and treatme ...

MacroGenics' valuation has declined due to continued bad news in 2024, impacting market sentiment. Click here to find out why ...

Terumo Vietnam Medical Equipment (Terumo Vietnam) and Daiichi Sankyo Vietnam have signed a Memorandum of Understanding (MoU) ...

Terumo Vietnam and Daiichi Sankyo Vietnam Co., Ltd. signed an MoU on February 26 to enhance cardiology expertise across ...